Skip to main content

Table 3 Number of patients with improvement from baseline BILAG B- and C-level activities

From: Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus

BILAG body system 6 weeksa 10 weeks 18 weeks
General (N = 14)b 6 (43%) 5 (36%) 2 (14%)
Mucocutaneous (N = 14) 11 (79%) 8 (57%) 6 (43%)
Neurological (N = 10) 7 (70%) 8 (80%) 6 (60%)
Musculoskeletal (N = 13) 9 (69%) 7 (54%) 4 (31%)
CV/Respiratory (N = 4) 3 (75%) 3 (75%) 3 (75%)
Vasculitis (N = 9) 4 (44%) 3 (33%) 3 (33%)
Renal (N = 4) 2 (50%) 1 (25%) 3 (75%)
Hematology (N = 12) 0 (0 %) 0 (0 %) 0 (0 %)
Overallc (N = 14) 13 (93%) 14 (100%) 13 (93%)
  1. aTwenty-four hours after fourth infusion. bN = number of patients with involvement in a particular body system at entry. cAs applied to any BILAG body system.